Pathos
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $500.0Mattributed |
|---|---|
| Latest round | series-d+, $365.0M, 2025-05-15attributed |
| Founded | 2020 |
| Headquarters | Cambridge, USA |
| Industry | bio |
| Stage | series-b+ |
| Website | pathos.com |
Pathos AI applies machine learning to drug development, using clinical and multi-omics data to design adaptive trials and identify responder populations. Pharma and biotech partners license the Pathos platform to accelerate Phase 2/3 trials. The company runs collaborative drug-development partnerships rather than only selling software.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-05-15 | series-d+ | $365.0M | undisclosed |
Detected tech stack
Nginx, React 16.13.1, reCAPTCHA, styled-components, parallax.js, PHP, Duda, jquery 3.7.0, friendly-challenge 0.9.8
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $365.0M | attributed | techcrunch named as publisher. No document URL on file. |
| Total raised $500.0M | attributed | techcrunch named as publisher. No document URL on file. |
| Company existence | self-reported | pathos.com, read 2026-05-07 |
| Description | self-reported | pathos.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.